June 2024 in “American Journal of Biomedical Science & Research” TH07 effectively promotes hair regrowth in androgenic alopecia with high patient satisfaction and no major side effects.
September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” Cancer prevention has advanced significantly, with some strategies proving successful.
September 2024 in “Journal of Cosmetic Dermatology” The new hair product quickly reduces hair shedding in women.
September 2025 in “Aesthetic Surgery Journal” Exosome therapies improve skin and hair rejuvenation effectively.
January 1994 in “Toxicological Sciences” Lower dosages of 2-(difluoromethyl)-dl-ornithine might reduce side effects, supporting further research.
Early genetic testing and new therapies like secukinumab are crucial for managing Netherton syndrome effectively.
March 2018 in “International Pharmacy Acta” New niosomal formulation effectively delivers aminexil through rat skin.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
September 2025 in “Journal of Dermatology Research Reviews & Reports” Rigenera® effectively improves hair condition in Androgenetic Alopecia, and HairMetrix® tracks progress well.
22 citations
,
September 2015 in “Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia” Recognizing and treating skin symptoms in essential thrombocythemia is crucial for patient quality of life.
7 citations
,
March 2020 in “Journal of the American Academy of Dermatology” EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.
15 citations
,
May 1987 in “Fundamental and applied toxicology” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” Exosomes show promise in dermatology but need more research and FDA approval for clinical use.
November 2025 in “Archives of Dermatological Research” Limelight (CB-EVs) safely promotes hair growth.
12 citations
,
January 2023 in “AAPS PharmSciTech”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
51 citations
,
January 2024 in “Nanoscale” Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
3 citations
,
March 2025 in “Arthritis Research & Therapy” Combining fat grafts with botulinum toxin helps improve Raynaud's symptoms.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Low-intensity ultrasound may protect hair follicles from damage caused by a common chemotherapy drug.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
January 2022 in “Aesthetic surgery journal”
Adding a topical agent to IPL improves hair reduction and satisfaction without extra side effects.
Hair intradermotherapy effectively treats hair loss and boosts self-esteem.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
July 2025 in “Journal of Investigative Dermatology”
June 2023 in “Italian journal of dermatology and venereology” The oral supplement improved hair loss in patients with telogen effluvium.
4 citations
,
June 2025 in “Molecules” Mediterranean Erica plants may help with inflammation, infections, and weight loss due to their bioactive compounds.